Simulations Plus Acquires Pro-ficiency For $100M, Expanding Reach Across Drug Development Spectrum
Portfolio Pulse from Benzinga Newsdesk
Simulations Plus has acquired Pro-ficiency for $100 million, expanding its capabilities across the drug development spectrum. This acquisition enhances Simulations Plus' offerings in clinical trial operations, medical affairs, and commercial market launches, integrating AI technologies for improved training, data analytics, and outcomes.
June 12, 2024 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Simulations Plus has acquired Pro-ficiency for $100 million, significantly expanding its capabilities in the drug development continuum. This acquisition is expected to enhance SLP's offerings in clinical trial operations, medical affairs, and commercial market launches, integrating AI technologies for better training, data analytics, and outcomes.
The acquisition of Pro-ficiency by Simulations Plus is a strategic move that significantly enhances SLP's capabilities in the drug development spectrum. The integration of AI technologies and expanded services in clinical trial operations, medical affairs, and market launches are likely to positively impact SLP's market position and financial performance in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100